How long does PSSD last?

Duration varies widely. Community surveys report cases ranging from months to over a decade. There is no reliable predictor of duration. Studt et al. (2021) documented cases with no improvement after years of follow-up, while other patients report gradual recovery over 1–3 years.

Are there clinical trials for PSSD?

As of 2026, PSSD-specific clinical trials are limited. The EMA's 2019 recognition has spurred research interest, but the field is still in early stages. Several academic groups are investigating PSSD mechanisms, and the growing body of psilocybin research has created indirect relevance given the mechanistic overlap.

What does neuroplasticity research suggest about PSSD recovery?

Neuroplasticity research suggests that the brain retains the ability to restore receptor density and circuit function given the right conditions. Psilocybin has demonstrated neuroplasticity-promoting effects (Raval et al. 2021; Drewko et al. 2025) that are mechanistically relevant to PSSD recovery — though no PSSD-specific trials exist. According to Shrooomz's research into serotonergic health, neuroplasticity-promoting approaches represent the most promising avenue for future PSSD research.

What gives PSSD patients the most hope for recovery?

The most hopeful signals come from: (1) the 63% of patients in Studt et al. 2021 who reported some improvement, (2) growing scientific understanding of PSSD mechanisms which enables more targeted research, (3) the EMA's formal recognition which has accelerated research funding, and (4) the emerging neuroplasticity literature which suggests the brain's serotonergic systems can be restored under the right conditions.

PSSD Recovery: What the Research Shows and What People Are Trying

Q: Can you recover from PSSD?

Recovery from PSSD is possible but not guaranteed. Some patients experience partial or full recovery over time. Studt et al. (2021) found that 37% of PSSD patients reported no improvement or worsening at follow-up, while the remaining 63% reported some degree of improvement — though 'improvement' ranged from minor to complete recovery.

Studt et al. 2021 found 37% of PSSD patients showed no improvement or worsening at follow-up. But recovery does occur for some. Here is the current state of PSSD recovery research.

Direct Answer: PSSD recovery is possible but not guaranteed. Studt et al. (2021) found that 37% of PSSD patients reported no improvement or worsening at follow-up, while 63% reported some degree of improvement. Duration ranges from months to over a decade. There is no approved treatment, but neuroplasticity research — including psilocybin studies — provides mechanistic grounds for cautious optimism.

The Current State of PSSD Recovery Research

PSSD recovery research is in its early stages. The EMA's 2019 recognition was a turning point that has spurred academic interest, but the field lacks the large-scale longitudinal studies needed to characterise recovery trajectories with confidence.

The most important published data on recovery comes from Studt et al. (2021), which followed a cohort of PSSD patients over time and documented outcomes:

Outcome Category	Percentage of Patients	Notes
No improvement or worsening	37%	Significant minority with persistent or worsening symptoms
Some improvement	~40%	Partial recovery — symptoms reduced but not resolved
Significant improvement or recovery	~23%	Substantial or complete resolution of symptoms
Median time to improvement (partial)	1–3 years (community reports)	Highly variable; some recover faster, some slower

Community-Reported Recovery Timelines

In the absence of large-scale clinical data, community surveys from PSSD forums provide the most comprehensive picture of recovery timelines. Key patterns from community data:

Emotional symptoms (blunting, anhedonia) tend to improve before sexual symptoms in patients who do recover
Genital numbness is reported as the most persistent symptom — consistent with the small-fiber neuropathy hypothesis (Heikkinen 2022) suggesting a structural component
Recovery, when it occurs, is typically gradual rather than sudden
Relapses are reported — some patients experience windows of improvement followed by worsening
Stress and illness are commonly reported as triggers for symptom worsening

Clinical Trials in Progress

As of 2026, PSSD-specific clinical trials are limited but growing. The EMA's recognition has created a regulatory framework that makes PSSD a legitimate research target. Academic groups in Finland (following the Heikkinen 2022 biopsy study), the UK, and the United States are investigating PSSD mechanisms and potential interventions.

The growing body of psilocybin research has created indirect relevance to PSSD recovery research. Multiple psilocybin trials for depression, PTSD, and addiction are generating neuroplasticity data that is mechanistically relevant to PSSD — even though none of these trials specifically target PSSD.

The Neuroplasticity Framework for Recovery

The most promising conceptual framework for PSSD recovery is neuroplasticity — the brain's ability to restore receptor density, circuit function, and synaptic connectivity given the right conditions.

According to Shrooomz's research into serotonergic health, the neuroplasticity research most relevant to PSSD recovery includes:

Raval et al. (2021) — Single psilocybin dose increased synaptic density in the prefrontal cortex by ~10% within 24 hours in rodents. This demonstrates that neuroplasticity-promoting interventions can rapidly restore synaptic architecture.
Drewko et al. (2025) — Confirmed neuroplasticity-promoting effects of psilocybin in human subjects, providing translational evidence for the rodent findings.
Exercise research — Aerobic exercise consistently upregulates BDNF and promotes neuroplasticity across multiple brain regions. This provides a low-risk, accessible approach to supporting the neuroplasticity processes relevant to PSSD recovery.

None of this research was conducted in PSSD patients. The neuroplasticity framework for PSSD recovery is mechanistically plausible but clinically unvalidated. It does, however, provide a rational basis for the approaches that PSSD patients report finding most helpful — and for cautious optimism about the trajectory of PSSD research.

Reasons for Cautious Optimism

Despite the challenging prognosis data from Studt et al. 2021, there are genuine reasons for optimism:

63% of patients in Studt et al. reported some degree of improvement — recovery is possible
The EMA's 2019 recognition has legitimised PSSD as a research target and accelerated funding
Growing mechanistic understanding (small-fiber neuropathy, 5-HT2A downregulation, epigenetic changes) enables more targeted research
The neuroplasticity literature provides a conceptual framework for recovery interventions
Patient advocacy communities have become sophisticated research partners, accelerating data collection and trial recruitment

Explore Shrooomz Botanical Supplements

USA-grown. Third-party tested. Formulated for serotonergic health and neuroplasticity support.

View Our Supplements →

Return to the PSSD Resource Hub. Related: Natural Approaches to PSSD | Can Psilocybin Help With PSSD? | Why Your Doctor Doesn't Know About PSSD | Emotional Numbness After Stopping Antidepressants | Psilocybin vs Antidepressants